Neutrophil activation has a pathogenic effect in inflammatory diseases. Protein 41 kinase B (PKB)/AKT regulates diverse cellular responses. However, the significance 42 of AKT in neutrophilic inflammation is still not well understood. Here, we identified 43 CLLV-1 as a novel AKT inhibitor. CLLV-1 inhibited respiratory burst, degranulation, 44 chemotaxis, and AKT phosphorylation in activated human neutrophils and dHL-60 45 cells. Significantly, CLLV-1 blocked AKT activity and covalently reacted with AKT 46 Cys310 in vitro. The AKT 309-313 peptide-CLLV-1 adducts were determined by NMR or 47 mass spectrometry assay. The alkylation agent-conjugated AKT (reduced form) level
This study aimed to identify the target protein of CLLV-1 in human neutrophils.
146
The fMLF mainly binds to formyl peptide receptor 1 (FPR1) to activate neutrophils 147 through multiple intracellular signaling pathways such as AKT and mitogen-activated 148 protein kinases (MAPKs) (Dorward et al, 2015) . CLLV-1 (0.1-3 μM) did not compete 
198
We suggest that CLLV-1 may directly target AKT per se to repress inflammation 199 in human neutrophils. To explore this hypothesis, the nonradioactive AKT kinase 
204

CLLV-1 covalently reacts with the thiol group of Cys310 in AKT
205
To determine how CLLV-1 blocked the AKT activity, the molecular docking of 206 CLLV-1 with AKT was performed. Based on CDOCKER and the CHARMm force field, 207 the CLLV-1-AKT binding modes were generated in receptor cavities with 10 poses.
208
The binding of CLLV-1 and AKT with the most favorable energy was estimated with
209
-CDOCKER (−474.532 kcal/mol). The p-benzoquinone, aromatic ring, or carboxyl 210 group of CLLV-1 were proposed to interact with the R273, D274, L275, C310, G311,
211
A317, L316, Y315, V320, or V330 residues of AKT ( Figure 6A-B 
234
To confirm the effect of CLLV-1 on AKT redox status in cells, we used the 
251
( Figure 8A ). The total protein levels were measured to represent the severity of Figure 8C ), suggesting the therapeutic potential of CLLV-1 in 260 neutrophil-dominant lung diseases. Together, CLLV-1 and MK-2206 successfully 261 impeded the inflammatory ALI in vivo, supporting that pharmacologically targeting 262 redox modification of AKT is a potential strategy for treating neutrophilic inflammation.
10
Discussion
265
Neutrophils are the most abundant leukocytes and play a significant role in 266 innate immunity. However, enhanced ROS generation and protease release by 267 activated neutrophils can cause cell and tissue damage (Nicolas-Avila et al, 2017;  268 Soehnlein et al, 2017) . The AKT pathway is known to be involved in many neutrophil 
287
has been identified; oxidized and dephosphorylated AKT is considered to have lost its 288 kinase activity (Ahmad et al, 2014; Durgadoss et al, 2012; Murata et al, 2003) .
289
Cys-to-Ser mutation at 296 and 310 in AKT prevents cadmium-inhibited AKT activity 290 and cell survival in neuroblastoma cells (Ahmad et al, 2014) , supporting the biological 291 significance of the critical Cys in AKT. In the present study, we found that fMLF 292 mitigated the oxidized AKT levels in dHL-60 cells, suggesting that the reduced form of
293
AKT corresponds to its active conformation. CLLV-1 repressed the alkylation 294 agent-labeled AKT levels (reduced form), and the AKT-PP2A interaction was 295 increased by CLLV-1.
296
CLLV-1 was proposed to interact with Cys310 of AKT by the molecular docking 297 model ( Figure 6A ). The adduct of AKT 309-313 peptides and CLLV-1 exhibited a new 298 singlet peak at δ 7.00 in the 1 H NMR spectrum ( Figure 6C ). The molecular masses of
299
AKT peptide-CLLV-1 adducts (AKT peptide + CLLV-1 -2H + Da) were also detected in 300 MALDI-TOF MS, AKT 309-313 -CLLV-1-Na, and AKT 307-328 -CLLV-1 ( Figure 6D -E),
11
suggesting that the reaction between AKT and CLLV-1 is an electrophilic addition. It 302 has been reported that thiol-based association between electrophilic compounds and 303 proteins possessed selectivity and specificity. The structural characteristic of proteins 304 and stereochemical structures of electrophiles results in their targeting selectivity 305 (Dennehy et al, 2006; Mi et al, 2011) . The redox modulations of ERK, JNK, or p38 306 have been characterized in response to intracellular ROS (Corcoran & Cotter, 2013) .
307
A low concentration of hydrogen peroxide (< 0.1 μM) induced the oxidation of Cys38 308 and Cys214 in ERK2 and increased phosphorylation of ERK2; in contrast,
309
doxorubicin-induced oxidation of ERK2 was accompanied by dephosphorylation (Galli 310 et al, 2008; Luanpitpong et al, 2012) . Upon exposure to a higher concentration of 311 hydrogen peroxide (> 10 μM), the cysteines of JNK2 (Cys41) and p38 (Cys162) were 312 oxidized, followed by activation and phosphorylation (Galli et al, 2008) . We found that 327 El-Benna et al, 2009; Kumar et al, 2014) . CLLV-1 dose-dependently restricted
328
AKT-mediated p47 phox phosphorylation and F-actin levels in fMLF-activated human 329 neutrophils and dHL-60 cells (Figures 1, 2 , and 4), confirming that CLLV-1-inhibited
330
AKT activity is critical for halting inflammatory activation in human neutrophils.
331
Developed AKT inhibitors are usually classified as ATP-competitive inhibitors and 332 allosteric inhibitors (Keane et al, 2014; Nitulescu et al, 2016) . ATP-competitive 333 inhibitors such as GSK690693 significantly suppress AKT activity; however, the 334 off-target effect is still of concern because of the ATP-binding site being highly 335 conserved among members of the AGC kinase family such as PKA and PKC (Jacinto & Lorberg, 2008) . A growing number of allosteric inhibitors with higher efficacy and 337 specificity, such as MK-2206, is being developed (Hirai et al, 2010) . The Cys296 and
336
338
Cys310 residues in the catalytic domain of AKT were identified as allosteric sites for 12 regulating AKT activity (Lee et al, 2010; Nitulescu et al, 2016; Shearn et al, 2012) .
340
Therefore, the Cys296 and Cys310 residues of AKT are potential therapeutic targets 341 in AKT-associated disorders. In this study, CLLV-1 was found to be a novel allosteric 342 inhibitor of AKT through covalently binding to Cys310 in vitro ( Figures 5B and 6 ). This 343 is the first example of restraining neutrophilic inflammation by pharmacologically 344 targeting the redox regulatory site of AKT. CLLV-1 showed anti-inflammatory effects in 345 human neutrophils and ameliorated LPS-primed ALI in mice (Figure 8) , supporting the 346 therapeutic potential of CLLV-1 in neutrophilic lung damage. Accordingly,
347
anti-inflammatory drugs that target the redox modification of AKT could potentially be 348 developed.
349
In summary, we demonstrate that AKT activation plays a critical role in 
358
CLLV-1 was synthesized by our group (Lee et al, 2008) . The CLLV-1 structure was 359 determined by 1 H nuclear magnetic resonance (NMR) spectrum analysis ( Figure 6C ).
360
The purity of CLLV-1 was higher than 96% as determined by HPLC. 
438
in the presence of CB (2.5 μg/mL) for 15 min at 37 °C. Elastase was obtained from 439 the supernatant of the cells after they were centrifuged at 1000 g for 5 min at 4 °C.
440
Then, the supernatant was equilibrated at 37 °C for 2 min and incubated with or The HL-60 cells were exposed to 1.3% DMSO for 5 days.
838
The differentiation of HL-60 cells by DMSO was examined by flow cytometry, using 
